Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer

Jennifer E. Klomp, J. Nathaniel Diehl, Jeffrey A. Klomp, A. Cole Edwards, Runying Yang, Alexis J. Morales, Khalilah E. Taylor, Kristina Drizyte-Miller, Kirsten L. Bryant, Antje Schaefer, Jared L. Johnson, Emily M. Huntsman, Tomer M. Yaron, Mariaelena Pierobon, Elisa Baldelli, Alex W. Prevatte, Natalie K. Barker, Laura E. Herring, Emanuel F. Petricoin, Lee M. GravesLewis C. Cantley, Adrienne D. Cox, Channing J. Der, Clint A. Stalnecker

Research output: Contribution to journalArticlepeer-review

Abstract

To delineate the mechanisms by which the ERK1 and ERK2 mitogen-activated protein kinases support mutant KRAS-driven cancer growth, we determined the ERK-dependent phosphoproteome in KRAS-mutant pancreatic cancer. We determined that ERK1 and ERK2 share near-identical signaling and transforming outputs and that the KRAS-regulated phosphoproteome is driven nearly completely by ERK. We identified 4666 ERK-dependent phosphosites on 2123 proteins, of which 79 and 66%, respectively, were not previously associated with ERK, substantially expanding the depth and breadth of ERK-dependent phosphorylation events and revealing a considerably more complex function for ERK in cancer. We established that ERK controls a highly dynamic and complex phosphoproteome that converges on cyclin-dependent kinase regulation and RAS homolog guanosine triphosphatase function (RHO GTPase). Our findings establish the most comprehensive molecular portrait and mechanisms by which ERK drives KRAS-dependent pancreatic cancer growth.

Original languageEnglish
Pages (from-to)eadk0850
JournalScience
Volume384
Issue number6700
DOIs
StatePublished - 7 Jun 2024
Externally publishedYes

Fingerprint

Dive into the research topics of 'Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer'. Together they form a unique fingerprint.

Cite this